Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio

BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.